Save time and get answers to complex questions with AI chat
Is januvia still on the market?When is xarelto's patent set to expire roughly?Allergan's patent for latisse expired?Brenzavvy discontinuation?What is the difference between apixaban and apixaban accord?
See the DrugPatentWatch profile for eliquis
What is Eliquis used to treat in atrial fibrillation? Eliquis, a brand name for apixaban, is an oral anticoagulant medication used to prevent stroke caused by atrial fibrillation not caused by heart valve problems [1]. Atrial fibrillation increases the risk of forming blood clots in the heart, which can travel to the brain and cause a stroke. Clinical trials and efficacy Clinical trials have consistently demonstrated the effectiveness of Eliquis in reducing the risk of stroke and systemic embolism in patients with atrial fibrillation [2]. The ARISTOTLE trial, a large randomized controlled study, found that Eliquis reduced the risk of stroke or systemic embolism by 21% compared to warfarin, a traditional anticoagulant medication [3]. Benefits compared to warfarin Compared to warfarin, Eliquis has several benefits, including: * Fewer bleeding complications, particularly fatal and intracranial bleeding [4] * Stable dosing, eliminating the need for regular blood tests and adjustments [5] * Rapid onset of action, allowing for immediate anticoagulation [6] Side effects and risks As with any medication, Eliquis carries potential side effects and risks. These include bleeding complications, gastrointestinal bleeding, and increased risk of stroke in patients with certain conditions [7]. It's essential to discuss these risks with your healthcare provider and weigh them against the benefits of taking Eliquis. Real-world effectiveness In real-world settings, Eliquis has been shown to be effective in reducing the risk of stroke and bleeding complications in patients with atrial fibrillation, according to data from various studies and registries [8]. Important notes When using Eliquis, it's essential to be aware of the need for regular monitoring of kidney function and liver enzyme levels [9]. Additionally, patients taking Eliquis should also be aware of the potential for bleeding complications and report any symptoms to their healthcare provider promptly. Sources: [1] DrugPatentWatch.com [2] ClinicalTrials.gov [3] ARISTOTLE Trial (2011) [4] New England Journal of Medicine (2013) [5] American Heart Association (2014) [6] European Medicines Agency (2012) [7] FDA.gov [8] Journal of the American College of Cardiology (2017) [9] European Heart Journal (2018)
Other Questions About Eliquis :